Could a vaccine stop colon cancer in lynch syndrome patients?

NCT ID NCT05419011

Ongoing Prevention Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase IIb trial tests whether a vaccine called Tri-Ad5, combined with an immune booster N-803, can prevent colon cancer in people with Lynch syndrome. The vaccine targets proteins found in precancer and cancer cells, aiming to train the immune system to destroy them. 186 participants will receive the vaccine or a placebo and be monitored for new growths or cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tri-Ad5 vaccine (targeting CEA, MUC1, Brachyury) plus N-803 (nogapendekin alfa)
What this could lead to: If it works, this could offer a way to prevent colon and other cancers in people with Lynch syndrome by training the immune system to destroy precancerous cells.
What could go wrong: This is a mid-stage trial with 186 participants, so results may not apply to everyone. The vaccine may not boost immunity enough, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm Colorectal Neoplasms, Hereditary Nonpolyposis Lynch syndrome colorectal cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA COLORECTAL NEOPLASM LYNCH SYNDROME

Contacts and locations

Locations

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UCSF Medical Center-Parnassus

San Francisco, California, 94143, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Arizona Cancer Center - Prevention Research Clinic

Tucson, Arizona, 85719, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Puerto Rico

San Juan, 00936, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.